Features | Partner Sites | Information | LinkXpress
Sign In
Primedic
Schiller
Ampronix

Protection Device Minimizes Brain Damage in Cardiovascular Procedures

By HospiMedica International staff writers
Posted on 02 Oct 2013
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
An innovative cerebral protection device (CPD) reduces the volume of new brain lesions, especially during protected transcatheter aortic valve replacement (TAVR).

The TriGuard CPD is a Nitinol mesh embolic debris deflection device designed to cover all three aortic cerebral branches to minimize the risk of brain damage during cardiovascular (CV) procedures, and accommodates most anatomical variations of the aortic arch. The Nitinol frame and mesh are designed to be flexible and atraumatic, yet robust and sturdy, thus providing simple placement and retrieval.

The device is placed via one of two femoral artery access ports typically used in TAVR, eliminating the need for a third puncture site, and deploys rapidly, self-positioning through a 3-mm catheter. Studies have shown that compared with historical data on unprotected TAVR procedures, use of the TriGuard CPD decreased maximum total lesion volume by 95%, while average total lesion volume was 57% smaller, when compared with historical references. The TriGuard Cerebral Protection Device is a product of Keystone Heart (Caesarea, Israel), and has received the European community CE marking of approval.

“Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. TriGuard is the most sophisticated cerebral embolic protection device currently available,” said Andreas Baumbach, MD, consultant cardiologist at University Hospitals Bristol (United Kingdom). “The device has the potential to become a routine preventive measure in TAVR and other cardiovascular procedures associated with embolic lesions.”

Cerebral emboli are commonly associated with left-sided cardiac procedures. During CV procedures, debris from the aortic valve, ascending aorta, and other sources may embolize and cause cerebral infarction. Cerebral damage may not be clinically evident after CV procedures and can take months or years for symptoms to manifest, often as devastating stroke, dementia, and cognitive decline. Embolic brain lesions can be objectively and consistently detected by diffusion-weighted magnetic resonance imaging (DW-MRI).

Related Links:

Keystone Heart
University Hospitals Bristol



Mercury Medical
JD Honigberg International
Armstrong Medical Industries
DeRoyal

Channels

Critical Care

view channel

Uric Acid Boosts Thrombolytic Therapy in Stroke

A new study reveals that uric acid (UA) in conjunction with intravenous thrombolytic therapy in patients suffering an acute ischemic stroke could help improve outcomes, particularly in women. Researchers at the University of Barcelona (UB; Spain), the Sunyer Biomedical Research Institute (Barcelona, Spain), and other... Read more

Women's Health

view channel

Prenatal Testing Can Detect Cancer in Mothers

A new study suggests that noninvasive prenatal testing (NIPT) for genetic anomalies could identify occult, previously undiagnosed maternal malignancies. Researchers at Tufts University Medical Center (Boston, MA, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and other institutions analyzed 125,426 samples... Read more

Business

view channel

Stryker to Acquire Muka Metal in Cash Transaction

Stryker Corporation (Kalamazoo, MI, USA) has announced a definitive agreement to acquire Muka Metal (Kayseri, Turkey). Stryker and Muka Metal, a leading manufacturer and marketer of hospital beds, stretchers, and related patient room furniture and accessories, have maintained a business relationship under a distribution... Read more
 

Events

31 Jul 2015 - 02 Aug 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.